1. Home
  2. ISOU vs ENTA Comparison

ISOU vs ENTA Comparison

Compare ISOU & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ISOU

IsoEnergy Ltd.

N/A

Current Price

$11.61

Market Cap

501.4M

Sector

N/A

ML Signal

N/A

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

N/A

Current Price

$14.19

Market Cap

486.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ISOU
ENTA
Founded
2016
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
501.4M
486.3M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
ISOU
ENTA
Price
$11.61
$14.19
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.40
AVG Volume (30 Days)
89.1K
176.6K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.93
EPS
N/A
N/A
Revenue
N/A
$102,814,000.00
Revenue This Year
N/A
$1.94
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.48
52 Week Low
$5.94
$4.09
52 Week High
$13.58
$17.15

Technical Indicators

Market Signals
Indicator
ISOU
ENTA
Relative Strength Index (RSI) 56.36 53.86
Support Level $9.62 $13.39
Resistance Level $13.58 $15.45
Average True Range (ATR) 0.65 0.80
MACD 0.09 0.06
Stochastic Oscillator 79.05 44.47

Price Performance

Historical Comparison
ISOU
ENTA

About ISOU IsoEnergy Ltd.

IsoEnergy Ltd is engaged in the acquisition, exploration, and evaluation of uranium properties in Canada. The company's project profile includes Thorburn Lake, Radio, Geiger, and Larocque East. and others. It operates in Canada, the United States, and Australia.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: